[8-K] Moleculin Biotech, Inc. Reports Material Event
Moleculin Biotech, Inc. furnished a new corporate presentation as Exhibit 99.1.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Moleculin Biotech, Inc. furnished a new corporate presentation as Exhibit 99.1. The company states this presentation is being used for its corporate presentation and is also posted on its website. The material is provided under Item 7.01 and is furnished, not filed, under the Exchange Act.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Moleculin Biotech (MBRX) disclose in this 8-K filing?
Moleculin Biotech furnished a corporate presentation as Exhibit 99.1. The company indicates this presentation is being used for its corporate presentation and is also posted on its website for informational purposes.
Under which item was Moleculin Biotech’s corporate presentation furnished?
The corporate presentation was furnished under Item 7.01. This item covers Regulation FD disclosures, which are typically informational updates provided to ensure broad, non-selective dissemination of company information.
Is Moleculin Biotech’s Exhibit 99.1 considered filed for Exchange Act purposes?
No, the company specifies that information in Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed filed under the Exchange Act. This distinction limits certain legal implications of the disclosure.
Can Moleculin Biotech’s Exhibit 99.1 be incorporated by reference into other SEC filings?
The company states Exhibit 99.1 will not be incorporated by reference into other Exchange Act or Securities Act filings unless specifically identified. This preserves flexibility over which documents formally include the presentation.
Who signed Moleculin Biotech’s March 19, 2026 8-K filing?
The 8-K filing dated March 19, 2026 was signed on behalf of Moleculin Biotech, Inc. by Jonathan P. Foster, as indicated in the signature block of the report.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): March 19, 2026
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
(Commission File No.)
|
(I.R.S. Employer Identification No.)
|
(Address of principal executive offices and zip code)
(713 ) 300-5160
(Registrant’s telephone number, including area code)
(Former name or former address, if changed from last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol (s)
|
Name of each exchange on which registered
|
|
|
|
The
|
|
Item 7.01
|
Regulation FD Disclosure
|
On March 19, 2026, Moleculin Biotech, Inc. (the “Company”) is using the attached presentation for its corporate presentation posted on the Company’s website and is set forth as Exhibit 99.1 herein.
The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (“Securities Act”), unless specifically identified therein as being incorporated by reference.
|
Item 9.01
|
Financial Statements and Exhibits.
|
|
(d)
|
Exhibits.
|
|
Exhibit No.
|
Description
|
|
99.1
|
Investor Presentation dated March 19, 2026
|
|
104
|
Cover page Interactive Data File (formatted as Inline XBRL document)
|
SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
MOLECULIN BIOTECH, INC.
|
|||
|
Date:
|
March 19, 2026
|
||
|
By:
|
/s/ Jonathan P. Foster
|
||
|
Jonathan P. Foster
|
|||
Exhibit 99.1
